医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EdiGENE Changes Name to Modalis Therapeutics

2019年08月29日 AM11:32
このエントリーをはてなブックマークに追加


 

TOKYO & CAMBRIDGE, Mass.

EdiGENE Corporation today announced that the company has changed its name to Modalis Therapeutics Corporation. Modalis (pronounced “MO-DA-LIS”) is an original name that the Company has chosen to hope Company’s proprietary gene modulation technology, CRISPR-GNDM, to be a new modality (therapeutic technology) to assist patients fighting with genetic disorders.

“Our goal is to create CRISPR based gene therapies for genetic disorders, most of which fall into orphan disease. We think there should be no disease that can be ignored because of the small patient population and that our belief, ’Every Life Deserve Attention’, is achievable with power of our new technology. We are proud to be a front runner of CRISPR based gene modulation therapy,” said Haru Morita, chief executive officer at Modalis Therapeutics. “We decided to change our company name because the Modalis better reflects the emerging gene modulation technology that Company established and provides to the industries”. In conjunction with the corporate name change, the Company will have a new domain name modalistx.com

About Modalis

Modalis is an emerging biotech company that develops therapeutics using its proprietary technology CRISPR-GNDM. Our people, products, and partners believe “every life deserves attention” and our mission is to develop therapeutics primarily for genetic orphan disorders that affect fewer than 200,000 people or fewer than 1 in 2,000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005804/en/

CONTACT

Modalis Therapeutics

Sawako Nakamura

media@modalistx.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作